• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

402例骨骼高级别骨肉瘤患者中3个不同年龄组的生存分析及预后因素。来自单一三级肉瘤中心的真实世界数据。

Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center.

作者信息

Evenhuis Richard E, Acem Ibtissam, Rueten-Budde Anja J, Karis Diederik S A, Fiocco Marta, Dorleijn Desiree M J, Speetjens Frank M, Anninga Jakob, Gelderblom Hans, van de Sande Michiel A J

机构信息

Department of Orthopedic Surgery, Leiden University Medical Center, 2300RC Leiden, The Netherlands.

Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, 3000CB Rotterdam, The Netherlands.

出版信息

Cancers (Basel). 2021 Jan 27;13(3):486. doi: 10.3390/cancers13030486.

DOI:10.3390/cancers13030486
PMID:33513855
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7865349/
Abstract

Age is a known prognostic factor for many sarcoma subtypes, however in the literature there are limited data on the different risk profiles of different age groups for osteosarcoma survival. This study aims to provide an overview of survival in patients with high-grade osteosarcoma in different age groups and prognostic variables for survival and local control among the entire cohort. In this single center retrospective cohort study, 402 patients with skeletal high-grade osteosarcoma were diagnosed and treated with curative intent between 1978 and 2017 at the Leiden University Medical Center (LUMC). Prognostic factors for survival were analyzed using a Cox proportional hazard model. In this study poor overall survival (OS) and event-free survival (EFS) were associated with increasing age. Age groups, tumor size, poor histopathological response, distant metastasis (DM) at presentation and local recurrence (LR) were important independent prognostic factors influencing OS and EFS. Differences in outcome among different age groups can be partially explained by patient and treatment characteristics.

摘要

年龄是许多肉瘤亚型已知的预后因素，然而在文献中，关于骨肉瘤生存方面不同年龄组的不同风险概况的数据有限。本研究旨在概述不同年龄组的高级别骨肉瘤患者的生存情况以及整个队列中生存和局部控制的预后变量。在这项单中心回顾性队列研究中，1978年至2017年期间，莱顿大学医学中心（LUMC）对402例骨骼高级别骨肉瘤患者进行了诊断并给予了根治性治疗。使用Cox比例风险模型分析生存的预后因素。在本研究中，总体生存率（OS）和无事件生存率（EFS）较差与年龄增长相关。年龄组、肿瘤大小、组织病理学反应差、初诊时远处转移（DM）和局部复发（LR）是影响OS和EFS的重要独立预后因素。不同年龄组之间结局的差异可部分由患者和治疗特征来解释。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c64/7865349/2317deeac8d3/cancers-13-00486-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c64/7865349/e6c7d029e199/cancers-13-00486-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c64/7865349/95fbc390a048/cancers-13-00486-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c64/7865349/307f435f3b33/cancers-13-00486-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c64/7865349/b4dae6c3daf3/cancers-13-00486-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c64/7865349/3ff5a7b85e91/cancers-13-00486-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c64/7865349/2317deeac8d3/cancers-13-00486-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c64/7865349/e6c7d029e199/cancers-13-00486-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c64/7865349/95fbc390a048/cancers-13-00486-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c64/7865349/307f435f3b33/cancers-13-00486-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c64/7865349/b4dae6c3daf3/cancers-13-00486-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c64/7865349/3ff5a7b85e91/cancers-13-00486-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c64/7865349/2317deeac8d3/cancers-13-00486-g006.jpg

相似文献

1
Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center.402例骨骼高级别骨肉瘤患者中3个不同年龄组的生存分析及预后因素。来自单一三级肉瘤中心的真实世界数据。
Cancers (Basel). 2021 Jan 27;13(3):486. doi: 10.3390/cancers13030486.
2
How Are Indeterminate Pulmonary Nodules at Diagnosis Associated with Survival in Patients with High-Grade Osteosarcoma?初诊时的不确定肺部结节与高级别骨肉瘤患者的生存有何关联？
Clin Orthop Relat Res. 2021 Feb 1;479(2):298-308. doi: 10.1097/CORR.0000000000001491.
3
Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma?肿瘤标本中微血管侵犯是否与高级别局限性骨肉瘤患者的预后较差有关？
Clin Orthop Relat Res. 2020 Jun;478(6):1190-1198. doi: 10.1097/CORR.0000000000001079.
4
Homogenous and Heterogenous Prognostic Factors for Patients with Bone Sarcoma.骨肉瘤患者的同质和异质预后因素。
Orthop Surg. 2021 Feb;13(1):134-144. doi: 10.1111/os.12851. Epub 2020 Dec 10.
5
A Novel System for the Surgical Staging of Primary High-grade Osteosarcoma: The Birmingham Classification.一种用于原发性高级别骨肉瘤手术分期的新系统：伯明翰分类法。
Clin Orthop Relat Res. 2017 Mar;475(3):842-850. doi: 10.1007/s11999-016-4851-y.
6
Can Multistate Modeling of Local Recurrence, Distant Metastasis, and Death Improve the Prediction of Outcome in Patients With Soft Tissue Sarcomas?局部复发、远处转移和死亡的多状态模型能否改善软组织肉瘤患者结局的预测？
Clin Orthop Relat Res. 2017 May;475(5):1427-1435. doi: 10.1007/s11999-017-5232-x. Epub 2017 Jan 12.
7
[Analysis of prognostic factors in osteosarcoma adult patients, a single institution experience].[成人骨肉瘤患者预后因素分析：单机构经验]
Klin Onkol. 2012;25(5):346-58.
8
Relative Wash-In Rate in Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a New Prognostic Biomarker for Event-Free Survival in 82 Patients with Osteosarcoma: A Multicenter Study.动态对比增强磁共振成像中的相对洗入率作为82例骨肉瘤患者无事件生存期的新预后生物标志物：一项多中心研究
Cancers (Basel). 2024 May 21;16(11):1954. doi: 10.3390/cancers16111954.
9
Analysis of prognostic factors and histopathological response to neoadjuvant chemotherapy in osteosarcoma.骨肉瘤新辅助化疗的预后因素及组织病理学反应分析。
Jt Dis Relat Surg. 2023;34(1):196-206. doi: 10.52312/jdrs.2023.902. Epub 2023 Jan 14.
10
Tumor grade and symptoms at presentation are survival risk factors in Chinese patients with primary retroperitoneal sarcoma.肿瘤分级和初诊时的症状是中国原发性腹膜后肉瘤患者的生存风险因素。
J Clin Transl Res. 2022 Nov 24;8(6):584-593. eCollection 2022 Dec 29.

引用本文的文献

1
Anlotinib combined with penpulimab in the treatment of advanced adult thoracic spinal osteosarcoma: a case report.安罗替尼联合派安普利单抗治疗成人晚期胸椎骨肉瘤：一例报告
Front Pharmacol. 2025 Jul 30;16:1599496. doi: 10.3389/fphar.2025.1599496. eCollection 2025.
2
Prognostic Factors in Newly Diagnosed High-Grade Osteosarcoma-A Systematic Review.新诊断的高级别骨肉瘤的预后因素——一项系统综述
Cancer Med. 2025 Jul;14(14):e71044. doi: 10.1002/cam4.71044.
3
Comparison of overall survival of adult and pediatric osteosarcoma patients using the national cancer database.

本文引用的文献

1
Lung metastases at the initial diagnosis of high-grade osteosarcoma: prevalence, risk factors and prognostic factors. A large population-based cohort study.高级别骨肉瘤初诊时的肺转移：患病率、危险因素及预后因素。一项基于人群的大型队列研究。
Sao Paulo Med J. 2019 Sep-Oct;137(5):423-429. doi: 10.1590/1516-3180.2018.0381120619.
2
Omic approaches to pediatric bone sarcomas.儿童骨肉瘤的 Omic 方法。
Pediatr Blood Cancer. 2020 Feb;67(2):e28072. doi: 10.1002/pbc.28072. Epub 2019 Nov 17.
3
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group.
利用国家癌症数据库比较成人和儿童骨肉瘤患者的总生存率。
BMC Cancer. 2025 Feb 18;25(1):290. doi: 10.1186/s12885-025-13496-3.
4
Advancing pediatric bone sarcoma care: navigating complications and innovating solutions in limb salvage and reconstruction-why, when, and how to treat limb length inequalities.推进儿科骨肉瘤治疗：保肢与重建中的并发症处理与创新解决方案——为何、何时以及如何治疗肢体不等长。
Acta Orthop Traumatol Turc. 2024 Jul 23;58(3):142-148. doi: 10.5152/j.aott.2024.24080.
5
Relative Wash-In Rate in Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a New Prognostic Biomarker for Event-Free Survival in 82 Patients with Osteosarcoma: A Multicenter Study.动态对比增强磁共振成像中的相对洗入率作为82例骨肉瘤患者无事件生存期的新预后生物标志物：一项多中心研究
Cancers (Basel). 2024 May 21;16(11):1954. doi: 10.3390/cancers16111954.
6
CCT6A is associated with CDC20, Enneking stage and prognosis in osteosarcoma, and its knockdown suppresses osteosarcoma cell viability and invasion.CCT6A与骨肉瘤中的CDC20、Enneking分期及预后相关，其敲低可抑制骨肉瘤细胞的活力和侵袭。
Oncol Lett. 2023 Apr 4;25(5):201. doi: 10.3892/ol.2023.13787. eCollection 2023 May.
7
Machine learning for predicting the survival in osteosarcoma patients: Analysis based on American and Hebei Province cohort.基于美国和河北省队列的骨肉瘤患者生存预测的机器学习分析。
Biomol Biomed. 2023 Sep 4;23(5):883-893. doi: 10.17305/bb.2023.8804.
8
More Data to Support a Cardiac-Oncologic Partnership.更多数据支持心脏肿瘤学合作关系。
JACC CardioOncol. 2023 Feb 21;5(1):128-130. doi: 10.1016/j.jaccao.2023.01.002. eCollection 2023 Feb.
9
Impact of Age at Diagnosis on Cardiotoxicity in High-Grade Osteosarcoma and Ewing Sarcoma Patients.诊断时年龄对高级别骨肉瘤和尤文肉瘤患者心脏毒性的影响
JACC CardioOncol. 2023 Feb 21;5(1):117-127. doi: 10.1016/j.jaccao.2022.11.016. eCollection 2023 Feb.
10
Bone sarcoma follow-up; a nationwide analysis of oncological events after initial treatment.骨肉瘤随访：初始治疗后肿瘤学事件的全国性分析
J Bone Oncol. 2022 Dec 9;38:100466. doi: 10.1016/j.jbo.2022.100466. eCollection 2023 Feb.
成骨肉瘤基础与转化生物学中的挑战性问题：儿童肿瘤学组的报告。
Cancer. 2019 Oct 15;125(20):3514-3525. doi: 10.1002/cncr.32351. Epub 2019 Jul 29.
4
Survival analysis of elderly patients with osteosarcoma.老年骨肉瘤患者的生存分析。
Int Orthop. 2019 Jul;43(7):1741-1747. doi: 10.1007/s00264-019-04332-y. Epub 2019 Apr 22.
5
Clinical Prognostic Factors and Outcome in Pediatric Osteosarcoma: Effect of Delay in Local Control and Degree of Necrosis in a Multidisciplinary Setting in Lebanon.黎巴嫩多学科背景下儿童骨肉瘤的临床预后因素与结局：局部控制延迟及坏死程度的影响
J Glob Oncol. 2019 Apr;5:1-8. doi: 10.1200/JGO.17.00241.
6
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.骨肉瘤的生存和预后：EURAMOS-1（欧洲和美国骨肉瘤研究）队列中 2000 多例患者的结果。
Eur J Cancer. 2019 Mar;109:36-50. doi: 10.1016/j.ejca.2018.11.027. Epub 2019 Jan 25.
7
The outcomes and prognostic factors in patients with osteosarcoma according to age: a Japanese nationwide study with focusing on the age differences.根据年龄分组的骨肉瘤患者的结局和预后因素：一项日本全国性研究，重点关注年龄差异。
BMC Cancer. 2018 May 31;18(1):614. doi: 10.1186/s12885-018-4487-2.
8
EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma.欧洲骨肉瘤老年患者化疗研究（EURO - B.O.S.S.）：40岁以上骨肉瘤患者化疗的欧洲研究：原发性高级别骨肉瘤的治疗结果
Tumori. 2018 Jan-Feb;104(1):30-36. doi: 10.5301/tj.5000696.
9
Tumor histopathological response to neoadjuvant chemotherapy in childhood solid malignancies: is it still impressive?儿童实体恶性肿瘤中肿瘤对新辅助化疗的组织病理学反应：它仍然令人印象深刻吗？
J Investig Med. 2018 Feb;66(2):289-297. doi: 10.1136/jim-2017-000531. Epub 2017 Sep 27.
10
Primary bone sarcomas in patients over 40 years of age: A retrospective study using data from the Bone Tumor Registry of Japan.40岁以上患者的原发性骨肉瘤：一项利用日本骨肿瘤登记处数据的回顾性研究。
J Orthop Sci. 2017 Jul;22(4):749-754. doi: 10.1016/j.jos.2017.03.008. Epub 2017 Apr 12.